

PREVENTION LAB - HIV & STI: CHANGE THE COURSE. PREVENT!

Roma, 28-29 aprile – Centro Congressi INMI Lazzaro Spallanzani

IRCCS

Chiars: Valentina Mazzotta, Francesco Vairo, Enrico Girardi, Andrea

Antinori

ECM 150-476032

DESTINATARI

Professione	Discipline
FARMACISTA	FARMACISTA PUBBLICO DEL SSN;
INFERMIERE	INFERMIERE;
TECNICO DELLA PREVENZIONE NELL'AMBIENTE E NEI LUOGHI DI LAVORO	TECNICO DELLA PREVENZIONE NELL'AMBIENTE E NEI LUOGHI DI LAVORO;

INFORMAZIONI GENERALI

Crediti Formativi: Sono stati assegnati all'evento n° 11 Crediti formativi, secondo il programma per l'Educazione Continua in Medicina (ID. evento N. 150-474443). L'assegnazione dei crediti formativi è subordinata alla presenza al 90% dei lavori e alla corretta compilazione di almeno il 75% delle domande proposte all'interno del questionario di valutazione finale. Saranno inoltre obbligatorie la rilevazione della presenza e la compilazione del questionario di gradimento dell'evento formativo.

Sede dell'evento: CENTRO CONGRESSI Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS – Via Portuense, 92 - 00153 Roma

Provider e Segreteria Scientifica

Effetti Srl - Via G.B. Giorgini, 16 – 20151 Milano

RAZIONALE

Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Epidemiological data from recent years

effetti srl

via G.B. Giorgini 16

20151 Milano, I

tel: +39 02 3343281

effetti@effetti.it

effetti@pec.effetti.it

www.effetti.it

www.makevent.it

p. IVA: 10756900154

cuu: USAL8PV

cap. soc.: € 100.000,00 i.v.

società conforme

al D.Lgs. 231/2001

show a stable incidence of new diagnoses, particularly among specific key populations, highlighting limitations in the implementation, access, and adherence to currently available prevention tools. These challenges are compounded by social and structural determinants, such as stigma, discrimination, and marginalization, which continue to hinder the effectiveness of prevention programs. The National Conference represents a highlevel scientific forum aimed at critically and multidisciplinarily analyzing HIV and related infection prevention strategies, integrating epidemiological evidence, public health models, therapeutic innovation, and person-centered approaches. The objective is to promote an up-to-date vision of combination prevention, aligned with international recommendations and the needs of the national context, with the goal of fostering continuous professional development among healthcare workers, encouraging the adoption of evidence-based preventive strategies, and contributing to the development of more

effective, equitable, and sustainable HIV prevention models. The program also addresses the role of social determinants of health, with particular attention to the impact of stigma and discrimination on access to prevention services. In this context, the identification and characterization of populations at higher risk represent a crucial step in the development of targeted and effective interventions. The use of risk assessment models and outcome indicators can enable the measurement of the impact of preventive strategies and guide evidence-based health

policies. In parallel, updates on HIV testing strategies and partner notification emphasize the importance of early diagnosis as a cornerstone of prevention. A central area of scientific discussion is dedicated to pre-exposure prophylaxis (PrEP), recognized as one of the most effective tools for HIV prevention. The program examines the current state of PrEP

implementation, with particular attention to delivery models, territorial dissemination, and challenges related to access, adherence, and retention. It also explores the role of community engagement and peer educators in improving the effectiveness of preventive interventions and reducing inequalities in access, particularly among populations such

as women, young people, migrants, and transgender individuals. The forward-looking perspective is further expanded through the analysis of long-acting PrEP formulations, from their biological foundations to clinical trial results and early implementation experiences. These new approaches represent a significant evolution in pharmacological prevention, with the potential to overcome some of the limitations of oral PrEP and to better address the needs of currently underserved populations. Another key pillar of the program is Treatment as Prevention (TasP), discussed both in the context

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

of rapid initiation of antiretroviral therapy in newly diagnosed individuals and in strategies for re-engagement in care and management of adherence challenges to antiretroviral therapy. The evidence supporting virological suppression as a prevention tool, in accordance with the U=U (Undetectable = Untransmittable) concept, is applied to complex clinical scenarios, including those characterized by high clinical

and social vulnerability. Finally, the program integrates HIV prevention with vaccination strategies in high-risk populations and in people with HIV, examining the role of anti-HPV, antipneumococcal-, and anti-Herpes Zoster vaccination in preventing comorbidities and long-term complications. This approach reflects a modern and integrated vision of prevention, aimed not only at reducing HIV transmission but also at improving overall health and quality of life.

The Conference is intended for Physicians specialized in Infectious Diseases, Hygiene and Public Health, Internal Medicine, Microbiology and Virology, Epidemiology.

PROGRAMMA

Day 1 – April 28th, 2026

10:30-11:00 Registration for participants

11:00-11:20 Welcome and opening

C. Matranga, A. Antinori, E. Girardi

11:20-11:50 OPENING LECTURE

Chairs: M.L. Cosmaro, C. Mussini

How contrast to stigma, marginalization and discrimination may improve access to prevention programs *J. Del Amo Valero*

11:50-12:00 Discussion

12:00-13:30 SESSION I - RISK ASSESSMENT AND MODELING FOR PREVENTION

Chairs: E. Girardi, A. Siddu

12:00-12:20 HIV key populations in Italy: assessing risk and targeting people *F. Vairo*

12:20-12:40 Reducing HIV incidence by PrEP expanding strategies *H. Wang*

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

12:40-13:00 Update on HIV testing strategies and indicator diseases *A. Skrzat-Klapaczyńska*

13:00-13:30 Panel discussion

13:30-14:30 Light lunch

14:30-16:00 SESSION II - PrEP CURRENT ASSESSMENT AND IMPROVEMENT

Chairs: A. Castagna, A. Cattelan

14:30-14:50 Towards the target: implementing and disseminating PrEP *J. Ghosn*

14:50-15:10 The oral PrEP hardcore in Italy: the PrIDE assessment *S. Nozza*

15:10-15:30 Community engagement and PrEP delivery: how to organise and promote it *C. Weber*

15:30-16:00 Panel discussion

16:00-16:30 Coffee break

16:30-18:15 SESSION III - STRATEGIES FOR EQUITY IN PREVENTION MODELS

Chairs: M. Farinella, F. Maggiolo

16:30-16:50 Language first: a powerful tool for breaking down barriers *F. Dragotto*

16:50-17:10 Improving PrEP adherence by navigators and peer educators *V.L. Del Negro*

17:10-17:30 PrEP for equity: women, young, migrants and transgender people
R. Rossotti

17:30-18:00 Panel discussion

18:00-18:15 Closing remarks

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

Day 2 – April 29th, 2026

09:00-10:30 SESSION IV - LA PrEP FOR THE PRESENT AND FUTURE

Chairs: M. Cernuschi, A. Gori

09:00-09:20 LA PrEP pipeline: from biologic models to clinical trial assessment
A. Calcagno

09:20-09:40 LA CAB for PrEP Italian landscape: the PrIDE perspective *D. Moschese*

09:40-10:00 Expanding PrEP access: is LA-PrEP the silver bullet? *E. Hoornenborg*

10:00-10:30 Panel discussion

10:30-11:00 Coffee break

11:00-12:30 SESSION V - TaSP IN THE PRESENT AND THE FUTURE

Chairs: G. Madeddu, C.M. Mastroianni

11:00-11:20 TaSP for naive people: the same-day starting model *V. Mazzotta*

11:20-11:40 TaSP in re-engagement of unsuppressed people with adherence challenges *M. Gandhi*

11:40-12:00 TaSP in HTE PWH: challenging and innovative strategies *R. Gagliardini*

12:00-12:30 Panel discussion

12:30-13:30 Light lunch

13:30-15:00 SESSION VI - VACCINE STRATEGIES FOR PREVENTION IN HIGH-RISK PEOPLE

Chairs: L. Sarmati, C. Torti

13:30-13:50 HPV vaccination and anal cancer screening in targeted risk population *E.N. Cavallari*

13:50-14:10 New frontiers of pneumococcal vaccination in immunocompromised people *M. Lichtner*

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.
società conforme
al D.Lgs. 231/2001

14:10-14:30 Herpes Zoster vaccination and protection of PWH from major cardiovascular events *M. Iannetta*

14:30-15:00 Panel discussion

15:00-15:15 Closing remarks

V. Mazzotta, F. Vairo, E. Girardi, A. Antinori

ACRONIMI

HIV: Human Immunodeficiency Virus

PrEP: Pre-exposure prophylaxis

TasP: Treatment as Prevention

U=U: Undetectable = Untransmittable

HPV: Human Papilloma Virus

PrIDE: Prevention ICONA Dedicated Ensemble

LA: long-acting

CAB: Cabotegravir

HTE PWH: [Heavily Treatment-Experienced](#) People with HIV

PWH: People with HIV

FACULTY

Andrea Antinori, INMI Lazzaro Spallanzani IRCCS, Roma

Andrea Calcagno, Università degli Studi del Piemonte Orientale "Amedeo Avogadro", Novara

Antonella Castagna, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano

Annamaria Cattelan, Azienda Ospedale-Università di Padova

Eugenio Nelson Cavallari, INMI Lazzaro Spallanzani IRCCS, Roma

Massimo Cernuschi, ASA Associazione Solidarietà AIDS ODV, Milano

Maria Luisa Cosmaro, Fondazione LILA Milano ETS, Milano

Julia Del Amo Valero, Instituto de Salud Carlos III, Madrid

Vito Leonardo Del Negro, Checkpoint Plus, Roma

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

Francesca Dragotto, Università degli Studi "Tor Vergata", Roma

Massimo Farinella, ANLAIDS, Roma

Roberta Gagliardini, INMI Lazzaro Spallanzani IRCCS, Roma

Monica Gandhi, UCSF-Bay Area Center for AIDS Research (CFAR), University of California, San Francisco (UCSF), San Francisco General Hospital HIV Clinic

Jade Ghosn, Bichat University Hospital, Université Paris Cité, Paris

Enrico Girardi, INMI Lazzaro Spallanzani IRCCS, Roma

Andrea Gori, ASST Fatebenefratelli Sacco, Università degli Studi di Milano

Elske Hoornenborg, Center for Sexual Health, GGD Amsterdam

Marco Iannetta, Università degli Studi "Tor Vergata", Roma

Miriam Lichtner, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso NESMOS, Sapienza Università di Roma, Azienda Ospedaliera Universitaria Sant'Andrea, Roma

Giordano Madeddu, Università degli Studi di Sassari

Franco Maggiolo, Direttore Scientifico SIMIT, Fabro (TR)

Claudio Maria Mastroianni, Sapienza Università di Roma

Cristina Matranga, INMI Lazzaro Spallanzani IRCCS, Roma

Valentina Mazzotta, INMI Lazzaro Spallanzani IRCCS, Roma

Davide Moschese, ASST Fatebenefratelli Sacco - Università degli Studi di Milano

Cristina Mussini, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena

Silvia Nozza, IRCCS Ospedale San Raffaele e Università Vita-Salute San Raffaele, Milano

Roberto Rossotti, ASST Grande Ospedale Metropolitano Niguarda, Milano

Loredana Sarmati, Università degli Studi "Tor Vergata", Roma

Andrea Siddu, Area Promozione della salute e prevenzione, D.R. Salute e Integrazione Sociosanitaria, Regione Lazio, Roma

Agata Skrzat-Klapaczyńska, Hospital for Infectious Diseases, Medical University of Warsaw

Carlo Torti, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma

Francesco Vairo, INMI Lazzaro Spallanzani IRCCS, Roma

Haoyi Wang, Department of Work and Social Psychology, Maastricht University, Maastricht

Christoph Weber, MD Checkpoint BLN, Berlin

effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001


Milano, 1 aprile 2026

La sottoscritta IDA TACCONI, nata a Milano l'11/09/1958, residente a Corsico (MI), codice fiscale TCCDIA58P51F205R, telefono 02.3343281, email ida.tacconi@effetti.it, in qualità di legale rappresentante del Provider accreditante Effetti, con sede legale in via G.B. Giorgini 16, Milano DICHIARA CHE

i curriculum vitae sono consultabili sul sito del Provider Effetti

www.makevent.it

In fede,



effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

IMQ SGQ CERTIFICAZIONE
UNI EN ISO 9001:2015